PERTH, Australia I December 22, 2014 I Phylogica Ltd (ASX: PYC), a public Australian drug discovery company, announced today that it has extended its collaboration with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), by entering into a Research and Licensing agreement to discover novel antibiotics.

Phylogica will employ its Phylome(r) drug discovery platform, including its proprietary cellpenetrating peptide discovery technology to identify Phylomer peptides suitable for further evaluation.

Under the terms of the agreement, Phylogica will receive an upfront payment of US$500,000. In addition, Phylogica is eligible to receive research, development, and commercialization milestone payments totaling up to US$142 million.

Phylogica’s CEO Dr Richard Hopkins commented that: “We are delighted to continue building upon on the success of our initial collaboration with Genentech. This alliance has the potential to address an unmet need for novel antimicrobials to treat bacterial infections, including drug- resistant superbugs. “

About Phylogica

Phylogica Limited (ASX: PYC) is a biotechnology company based in Perth, Australia with a world-class drug discovery platform harnessing the rich biodiversity of nature to discover novel peptide therapeutics from the most structurally diverse libraries available. The Company listed on the ASX in 2005 as a spin out from the Telethon Institute for Child Health Research (Perth, Australia) and the Fox Chase Cancer

Centre (Philadelphia, USA). The Company’s drug discovery platform is based on its proprietary Phylomer(r)

BRE AK T H RO U G H     P E P T I D E     TH ER A PEU TI C S

Libraries containing over 400 billion unique natural peptides, which have been optimised by evolutionary selection to adopt stable drug-like structures. Phylogica offers fully integrated drug discovery services to the pharmaceutical industry utilising its Phylomer(r)   libraries and proprietary screening technologies in exchange for licence fees, milestones and royalties. Phylogica has entered into discovery alliances with several of the largest global Pharmaceutical companies. Partners from alliances within the last 5 years include Roche, Genentech, MedImmune, Pfizer, Janssen and Cubist Pharmaceuticals.

SOURCE: Phylogica